More news: Health / Surgery
Agency / Source: General Electric Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PnuVax to Acquire Inactivated Yellow Fever Vaccine Intellectual Property from GE Healthcare - Companies to optimize manufacturing process using GE FlexFactory - /
PnuVax to Acquire Inactivated Yellow Fever Vaccine Intellectual Property from GE Healthcare


PRZOOM - /newswire/ - Chalfont St Giles, United Kingdom, 2016/06/08 - Companies to optimize manufacturing process using GE FlexFactory - / NYSE: GE

Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


PnuVax Incorporated (PnuVax), a vaccine and biopharmaceutical company, and GE Healthcare’s Life Sciences business announced today that they have entered an agreement under which PnuVax can acquire GE Healthcare’s intellectual property (IP) relating to an inactivated yellow fever vaccine. Under the terms of the agreement, PnuVax will purchase a GE Healthcare Life Sciences FlexFactory™ biomanufacturing platform and the two companies plan a collaboration to optimize the manufacturing process for the new vaccine. Financial terms were not disclosed.

Yellow fever is an acute viral hemorrhagic disease transmitted by mosquitoes and is endemic in tropical Africa and Central and South America. The World Health Organization estimated the burden of yellow fever during 2013 was 84 000 170 000 severe cases and 29 000 60 000 deaths worldwide (1). The WHO and the Centers for Disease Control and Prevention (CDC) in the US have advised that yellow fever vaccine supplies are constrained at this time (2). Currently, immunization against yellow fever is carried out using a live vaccine, 17D.

While generally regarded as safe and highly effective, the live vaccine can cause serious side effects in certain groups of people such as the elderly, people with severe immunodeficiency and people with a severe egg allergy (3). These side effects have driven research efforts to develop an inactivated non-replicating vaccine, with the aim of allowing more people to be safely vaccinated against yellow fever.

GE Healthcare Life Sciences acquired the IP to the inactivated cell-culture based vaccine, XRX 001, which may reduce the incidence of serious side effects associated with the live vaccine, as a part of the acquisition of Xcellerex Inc. in 2012. In 2011, positive results of a Phase 1 clinical trial (4) were announced for the vaccine, which demonstrated a 100% seroconversion rate. GE Healthcare has continued to optimize the manufacturing process for the vaccine.

Donald Gerson CEO, PnuVax Incorporated, said: “Yellow fever remains a significant and persistent public health problem in Africa and South America. Increased worldwide travel and expanding mosquito populations further exacerbate the risk of yellow fever outbreaks, as seen in the current outbreak in Africa(5). Management of the disease depends on preventive vaccination to protect residents and travelers who may be exposed to the virus. PnuVax is committed to ensuring global access to high-quality, safe, effective and low-cost vaccines."

"We believe the benefits of the single-use based FlexFactory system will allow localization of Yellow Fever Vaccine production to endemic areas Yellow Fever Vaccine production to endemic areas and will provide a platform for manufacturing other similar vaccines to respond to emerging pathogens in the future.”

GE Healthcare’s FlexFactory is a start-to-finish biomanufacturing platform based on single-use technologies that increases productivity by simplifying and accelerating bioprocessing and reducing time-consuming routines, such as cleaning and sterilization. It also provides flexibility to modify the manufacturing processes when production needs change or even to develop a completely new production line. It is designed to help manufacturers such as PnuVax to rapidly respond to local healthcare needs and to support significant demand in an epidemic situation.

Parrish Galliher, Chief Technology Officer, Upstream BioProcess, GE Healthcare Life Sciences, added: “We are delighted PnuVax will be continuing the development of XRX 001 and that they have chosen GE Healthcare to help design and optimize the manufacturing process for this vaccine. We look forward to working with the talented team at PnuVax to help bring better health to more people.”

(1). WHO: Yellow Fever Link:
(2). US CDC: Yellow Fever Link:;
WHO: Yellow Fever Link:
(3). WHO: Yellow Fever Link:
(5). N Engl J Med 2011;364:1326-33

About GE Healthcare
GE Healthcare ( provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

About PnuVax Incorporated
PnuVax Incorporated ( is dedicated to the production of high quality vaccines and biopharmaceuticals for the promotion of public health worldwide. PnuVax uses the best available technologies to manufacture vaccines that are affordable for the children of lower income nations. For more information about Pnuvax, visit our website at

PnuVax Incorporated Media Contact: Jonas Gerson - Business Development
T: +1 438-288-0746 - E: contact[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: General Electric Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!

PnuVax to Acquire Inactivated Yellow Fever Vaccine Intellectual Property from GE Healthcare

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
GE FlexFactory | PnuVax Incorporated
Contact: Saara Nordenström - GE Healthcare 
+46 7386 81286 saara.nordenstrom[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From General Electric Company / Company Profile

Read Health / Surgery Most Recent Related Press Releases:

AGS Health, A Global Leader in Revenue Cycle Management Solutions Establishes Operations in Jaipur, India
Next-generation Diagnostics Paving the Way to Reach Personalized Medicine According to Frost & Sullivan
InterSystems Partners with the Rhodes Group to Improve Hepatitis C Treatment in New Mexico
BostonGene Announces 0 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
Roche Diagnostics India Earns the Frost & Sullivan 2021 India Competitive Strategy Leadership Award
Wolters Kluwer Lauded by Frost & Sullivan for Enabling Aligned Decision-making with its Clinical Decision Support Solutions
Syapse Awarded 2021 Technology Innovation Leadership Award by Frost & Sullivan for Accelerating Real-world Care Delivery
Lumeon Commended by Frost & Sullivan for Enabling Digital Transformation in Healthcare
Payment Integrity Solutions Enable Healthcare Plans to Optimize Processes and Maximize Returns Finds Frost & Sullivan
Menopause to Become the Next Game-changer in the Global Femtech Solutions Industry by 2025 Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Luxury Executive Wellness

Visit  La Bella Bakery Artisan Bakery Arizona


  ©2022 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today